Business

Trump injured but ‘fine’ after assassination attempt; FBI identifies gunman

Published

1 month ago

July 14, 2024

Jill Colvin, Julie Carr Smyth, Eric Tucker, Michelle L. Price, Colleen Long, Michael Balsamo, The Associated Press

Former President Donald Trump was the target of an assassination attempt Saturday at a Pennsylvania rally, days before he was to accept the Republican nomination for a third time. A barrage of gunfire set off panic, and a bloodied Trump, who said he was shot in the ear, was surrounded by Secret Service and hurried to his SUV as he pumped his fist in a show of defiance.

Trump’s campaign said the presumptive GOP nominee was doing “fine” after the shooting, which he said pierced the upper part of his right ear.

“I knew immediately that something was wrong in that I heard a whizzing sound, shots, and immediately felt the bullet ripping through the skin. Much bleeding took place,” he wrote on his social media site.

The FBI early Sunday named Thomas Matthew Crooks, 20, of Bethel Park, Pennsylvania, as the subject involved in the assassination attempt. The agency said the investigation remains active and ongoing.

One attendee was killed and two spectators were critically injured, authorities said. All were identified as men. The Secret Service said it killed the suspected shooter — who it said attacked from an elevated position outside the rally venue, a farm show in Butler, Pennsylvania — and said Trump was safe.

The FBI said during a press conference late Saturday that they were not prepared to release the identity of the shooter and had not yet identified a motive for the assassination attempt.

The attack was the most serious attempt to assassinate a president or presidential candidate since Ronald Reagan was shot in 1981. It drew new attention to concerns about political violence in a deeply polarized U.S. less than four months before the presidential election. And it could alter the tenor and security posture at the Republican National Convention, which will begin Monday in Milwaukee.

Organizers said the convention would proceed as planned.

Trump flew to New Jersey after visiting a local Pennsylvania hospital, landing shortly after midnight at Newark Liberty International Airport. Video posted by an aide showed the former president deplaning his private jet flanked by U.S. Secret Service agents and heavily armed members of the agency’s counter assault team — an unusually visible show of force by his protective detail.

President Joe Biden, who is running against Trump, was briefed on the incident and spoke to Trump several hours after the shooting, the White House said.

“There’s no place in America for this type of violence,” the president said in public remarks. “It’s sick. It’s sick.”

Biden planned to return to Washington early, cutting short a weekend at his beach home in Rehoboth Beach, Delaware.

Many Republicans quickly blamed the violence on Biden and his allies, arguing that sustained attacks on Trump as a threat to democracy have created a toxic environment. They pointed in particular to a comment Biden made to donors on July 8, saying “it’s time to put Trump in the bullseye.”

In the coming days, much of the focus will shift to the shooter and security lapses. The shooter was not an attendee at the rally and was killed by U.S. Secret Service agents, according to two officials who spoke to the Associated Press on the condition of anonymity to discuss the ongoing investigation.

The officials said the shooter was engaged by members of the U.S. Secret Service counterassault team. The heavily armed tactical team travels everywhere with the president and major party nominees and is meant to confront any active threats while other agents focus on safeguarding and evacuating the person at the center of protection.

Law enforcement recovered an AR-style rifle at the scene, according to a third person familiar with the matter who spoke on condition of anonymity to discuss the ongoing investigation.

An AP analysis of more than a dozen videos and photos from the scene of the Trump rally, as well as satellite imagery of the site, shows the shooter was able to get astonishingly close to the stage where the former president was speaking. A video posted to social media and geolocated by the AP shows the body of a person wearing gray camouflage lying motionless on the roof of a building at AGR International Inc., a manufacturing plant just north of the Butler Farm Show grounds where Trump’s rally was held.

The roof where the person lay was less than 150 meters (164 yards) from where Trump was speaking, a distance from which a decent marksman could reasonably hit a human-sized target. For reference, 150 meters is a distance at which U.S. Army recruits must hit a scaled human-sized silhouette to qualify with the M-16 rifle. The AR-15, like the shooter at the Trump rally had, is the semi-automatic civilian version of the military M-16.

Asked at the press conference whether law enforcement did not know the shooter was on the roof until he began firing, Kevin Rojek, Special Agent in Charge of the FBI’s Pittsburgh Field Office, responded that “that is our assessment at this time”

“It is surprising” that the gunman was able to open fire on the stage before the Secret Service killed him, he added.

Homeland Security Secretary Alejandro Mayorkas, whose department oversees the Secret Service, said officials were engaged with the Biden and Trump campaigns and “taking every possible measure to ensure their safety and security.”

A rally disrupted by gunfire

Trump was showing off a chart of border crossing numbers when the gunfire began after 6:10 p.m.

As the first pop rang out, Trump said, “Oh,” and the raised his hand to his right ear and looked at it, before quickly crouching to the ground behind his lectern. The people in the stands behind him also crouched down as screams rang through the crowd.

Someone could be heard near the microphone saying, “Get down, get down, get down, get down!” as agents rushed to the stage. They piled atop the former president to shield him with their bodies, as is their training protocol, as other agents took up positions on stage to search for the threat.

Screams were heard in the crowd of several thousand people. A woman screamed louder than the rest. Afterward, voices were heard saying “shooter’s down” several times, before someone asked “are we good to move?” and “are we clear?” Then, someone ordered, “Let’s move.”

Trump could be heard on the video saying at least twice, “Let me get my shoes, let me get my shoes,” with another voice heard saying, “I’ve got you sir.”

Trump got to his feet moments later and could be seen reaching with his right hand toward his face, which was smeared with blood on his face. He then pumped his fist in the air and appeared to mouth the word “Fight” twice his crowd of supporters, prompting loud cheers and then chants of “USA. USA. USA.”

The crowd cheered as he got back up and pumped his fist.

His motorcade left the venue moments later. Video showed Trump turning back to the crowd and raising a fist right before he was put into a vehicle.

Witnesses heard multiple gunshots and ducked for cover

“Everybody went to their knees or their prone position, because we all knew, everyone becoming aware of the fact this was gunfire,” said Dave McCormick, the Republican candidate for U.S. Senate in Pennsylvania, who was sitting to Trump’s right on stage.

As he saw Trump raise his fist, McCormick said, he looked over his shoulder and noticed someone had been hit while sitting in the bleachers behind the stage.

Eventually, first responders were able to carry the injured person out of a large crowd so he could get medical care, McCormick said.

Reporters covering the rally heard five or six shots ring out and many ducked for cover, hiding under tables. After the first two or three bangs, people in the crowd looked startled, but not panicked. An AP reporter at the scene reported the noise sounded like firecrackers at first or perhaps a car backfiring.

When it was clear the situation had been contained and that Trump would not be returning to speak, attendees started filing out of the venue. One man in an electric wheelchair got stuck on the field when his chair’s battery died. Others tried to help him move.

Police soon told the people remaining to leave the venue and Secret Service agents told reporters to get “out now. This is a live crime scene.”

Two firefighters from nearby Steubenville, Ohio, who were at the rally told the AP that they helped people who appeared injured and heard bullets hitting broadcast speakers.

“The bullets rattled around the grandstand, one hit the speaker tower and then chaos broke. We hit the ground and then the police converged into the grandstands, said Chris Takach.

“The first thing I heard is a couple of cracks,” Dave Sullivan said.

Sullivan said he saw one of the speakers get hit and bullets rattling and, “we hit the deck.”

He said once Secret Service and other authorities converged on Trump, he and Takach assisted two people who may have been shot in the grandstand and cleared a path to get them out of the way.

“Just a sad day for America,” Sullivan said.

“After we heard the shots got fired, then the hydraulic line was spraying all around, you could see the hydraulic fluid coming out of it. And then the speaker tower started to fall down,” Sullivan said. “Then we heard another shot that, you could hear, you knew something was, it was bullets. It wasn’t firecrackers.”

Political violence again shakes America

The perils of campaigning took on a new urgency after the assassination of Robert F. Kennedy in California in 1968, and again in 1972 when Arthur Bremer shot and seriously hurt George Wallace, who was running as an independent on a campaign platform that has sometimes been compared to Trump’s. That led to increased protection of candidates, even as the threats persisted, notably against Jesse Jackson in 1988 and Barack Obama in 2008.

Presidents, particularly after the assassination of John F. Kennedy in 1963, have even greater layers of security. Trump is a rarity as both a former president and a current candidate.

North Dakota Gov. Doug Burgum, Florida Sen. Marco Rubio and Ohio Sen. JD Vance, the three men on Trump’s shortlist for vice president, all quickly sent out statements expressing concern for the former president, with Rubio sharing an image taken as Trump was escorted off stage with his fist in the air and a streak of blood on his face along with the words “God protected President Trump.”

Pennsylvania Gov. Josh Shapiro, a Democrat, said in a statement on X that he had been briefed on the situation and Pennsylvania state police were on hand at the rally site.

“Violence targeted at any political party or political leader is absolutely unacceptable. It has no place in Pennsylvania or the United States,” he said.

Source link

Up Next

Battery maker’s surge raises hope of turnaround for EV vehicles sales

Don't Miss

Chancellor Rachel Reeves has made her opening gambit. What’s her long game?

Click to comment

Business

Denmark gets Novo Nordisk to lower Ozempic prices

Published

7 days ago

August 7, 2024

Arthur Allen, KFF Health News

On May 13, Sen. Bernie Sanders (I-Vt.) published an open letter to Novo Nordisk on the front page of a leading Danish newspaper, urging the hometown company to live up to its altruistic standards by lowering U.S. prices for its blockbuster diabetes and weight loss drugs.

What Sanders didn’t realize was that Denmark, a country of 6 million, was enduring its own crisis over how to pay for the Novo Nordisk drugs Ozempic and Wegovy.

Most other developed countries, including Denmark, negotiate down drug costs for their citizens, paying prices that are a fraction of those in the United States. But when a drug is effective and expensive, pharmaceutical companies can play hardball on pricing. And Novo Nordisk did, at least initially, pushing the Danish health system to its limits.

The country’s socialized health system had for years covered Ozempic as a diabetes treatment, but in 2022 doctors began prescribing it for weight loss, too, and soon they “emptied all the money boxes in the entire public health system,” said University of Copenhagen professor Jens Juul Holst, a co-inventor of the drug.

Countries around the world are struggling with how and when to pay for Ozempic, Eli Lilly’s Mounjaro, and other drugs in the same chemical class, particularly when they are prescribed for weight loss. Indeed, the sky-high prices paid in the U.S. set a bar that pharmaceutical companies can use as they negotiate with other health systems.

In Denmark, with prescriptions for the drugs gobbling up 18% of regional drug budgets in 2023, officials were considering the unthinkable in a system that prides itself on free cradle-to-grave coverage: forcing patients to pay out-of-pocket for Ozempic — a drug made in the country.

In America, meanwhile, tightening insurance policies are making it harder for patients to get the drugs, which are listed at up to $1,350 a month.

“There are changes month to month in our clinic in terms of the supply, coverage, which drug is available,” said Michael Blaha, director of clinical research for the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease. He said that doctors and patients were “playing a constant game of prior authorization and appeals.”

In particular, use of the drugs for weight loss is a hot-button issue. Novo Nordisk and Lilly are battling for coverage — joined by some doctors and patient advocate groups, many funded by the drug companies. They are pressing to overturn a 2005 federal rule that prohibits Medicare from reimbursing weight loss treatments.

“There’s a strong assumption that Medicare is going to cover these drugs for obesity treatment sooner or later,” said David Kim, an assistant professor of medicine and public health sciences at the University of Chicago. If Medicare pays, he added, commercial insurers will probably follow suit.

The impact on federal and commercial insurance budgets, he said, depends on three unanswered questions: How many people will eventually get the drugs? For how long will they take them? And at what price?

The potential Medicare market alone is enormous. In 2020 about 13.7 million Medicare beneficiaries, around a quarter of the total, were diagnosed as overweight or obese, according to Juliette Cubanski and Tricia Neuman, researchers at KFF, a health information nonprofit that includes KFF Health News. Assuming a 50% discount on a $1,300 monthly list price for Wegovy, that’s a $107 billion price tag. The entire federal share of Medicare Part D spending in 2024 was projected to be $120 billion.

Novo Nordisk spent $7.6 million lobbying Congress over the past 12 months, and lobbying disclosures show that most of that was to promote bills in the House and Senate to expand use of the GLP-1 drugs.

Pressure from drugmakers has been relentless. Pfizer, which has a GLP-1 drug in development, commissioned a white paper by consultancy Manatt arguing that Medicare law already allows payment for these anti-obesity drugs, since they have benefits beyond weight loss. Novo and other pharmaceutical companies have funded research that shows health care savings on chronic disease through use of the drugs.

But the Congressional Budget Office, whose judgments about the cost of such policies weigh heavily in whether they are eventually adopted, has yet to give a final opinion. In a March presentation, the office said it was “not aware of empirical evidence that directly links the use of anti-obesity medicines to reductions in other health care spending.”

Prime Therapeutics, a pharmacy benefit manager whose clients are employers that fund drug plans, released a study this year finding that only a third of patients put on a GLP-1 drug stayed on it for a full year. That means insurance coverage of the drugs could sometimes be a waste of money, said Patrick Gleason, Prime Therapeutics’ leader of research, since research shows that patients tend to gain the weight back after cessation.

That doesn’t completely surprise Holst, the Danish scientist, who said the GLP-1 drugs’ suppression of appetite is for many people “so miserably boring that you can’t stand it any longer and you have to go back to your old life.”

One answer might be weight loss programs that employ the GLP-1s for, say, a year, followed by maintenance therapy with cheaper drugs, Kim said.

One way or another, many experts in the field say, it’s sensible to cover weight loss before the onset of the chronic illnesses associated with obesity, like Type 2 diabetes.

Indeed, because obesity is associated with so many comorbidities, drugmakers are now doing studies showing that GLP-1 drugs also show positive impact on conditions like sleep apnea and heart, liver, and kidney diseases.

Yet even advocates for the drugs’ use acknowledge uncertainty about how long it would take for such health benefits to kick in, or whether shorter-term use would prevent or ameliorate longer-term illnesses.

“Modeling the impacts is complicated,” said Alison Sexton Ward, a research scientist at the University of Southern California’s Schaeffer Center for Health Policy and Economics. “Medical costs won’t go down immediately. The prevented diseases may be years in the future.”

Starting next year, Medicare beneficiaries’ Part D out-of-pocket costs will be capped at $2,000, meaning U.S. taxpayers will foot the bill for most Medicare drug expenses. So it’s no surprise the Congressional Budget Office believes the government will launch Medicare price negotiations for semaglutide under the Inflation Reduction Act “within the next few years,” per its March presentation.

According to the terms of the act, Ozempic would be eligible for government price negotiation as early as next year, with new prices reflected in 2027. The negotiated unit price would apply to all forms of the drug — Ozempic; its higher-dose, weight loss-branded version, Wegovy; and a pill, Rybelsus.

Where the price would land is unclear. Wegovy costs patients up to $365 a month in Denmark, which typically doesn’t cover the drug — and about $140 in Germany and $92 in the U.K.

Meanwhile, generic drugmakers are gearing up to sell their versions of semaglutide. Those appear set to go on sale in China and Brazil as early as 2026. Americans are likely to have to wait until at least 2032 because of U.S. patent restrictions. The Federal Trade Commission has tried to nibble at the drugs’ exclusivity periods by challenging Novo Nordisk patent filings on applicators used to inject the drugs — which would extend their market exclusivity up to 30 months.

For now, patients who can’t afford or access the drugs often turn to compounded forms, which are not FDA-approved although their raw material comes from FDA-registered factories. Blaha has “a number of patients” who can’t access the branded drugs and show up at the clinic with compound drug vials.

Two weeks before Sanders published his letter in Denmark, Novo Nordisk cut the local price of Ozempic by 34%, to $130 a month — about 15% of its U.S. list price. The government, which had warned it would stop paying for the drug, agreed to cover Ozempic diabetes treatment, but only for patients who had first tried a cheaper medicine such as metformin.

Wegovy, the same medicine but at a higher dose, targeted to weight loss, would in nearly all cases remain the patient’s responsibility at $365 monthly, a price that, while modest by U.S. standards, has sparked intense discussions about the uneven impact of class on its affordability, said Nils Jakob Knudsen, an endocrinologist in Copenhagen.

The calculus of the drugs’ price is complex for the Danes, he added, because “the blooming economy for Novo is also driving our very healthy Danish economy.”

Novo Nordisk’s market valuation of $591 billion on Aug. 2 was considerably higher than the entire GDP of Denmark.

Source link

Business

Weekly mortgage refinance demand soars 16% as rates sink to lowest level in over a year

Published

7 days ago

August 7, 2024

Diana Olick

An aerial view shows a subdivision that has replaced the once rural landscape in Hawthorn Woods, Illinois.

Scott Olson | Getty Images

Mortgage interest rates dropped last week to the lowest level since May 2023, causing a surge in mortgage demand from both homebuyers and especially current homeowners.

Total mortgage application volume rose 6.9% last week compared with the previous week according to the Mortgage Bankers Association’s seasonally adjusted index. Volume was at the highest level since January of this year.

The average contract interest rate for 30-year fixed-rate mortgages with conforming loan balances ($766,550 or less) decreased to 6.55% from 6.82%, with points decreasing to 0.58 from 0.62 (including the origination fee) for loans with a 20% down payment.

“Mortgage rates decreased across the board last week…following doveish communication from the Federal Reserve and a weak jobs report, which added to increased concerns of an economy slowing more rapidly than expected,” said Joel Kan, MBA’s vice president and deputy chief economist in a release.

Applications to refinance a home loan, which are most sensitive to weekly rate changes, jumped 16% for the week and were 59% higher than the same week one year ago. While the percentage increases are large, they are still coming off a very small base. The vast majority of borrowers today have loans with rates below 5%. There are less than one million borrowers who can benefit from a refinance and shave at least 75 basis points off their current rate.

Applications for a mortgage to purchase a home increased just 1% for the week but were still 11% lower than the same week one year ago.

“Despite the downward movement in rates, purchase activity only saw small gains, with an increase in conventional purchase applications offset by decreases in government purchase applications. For-sale inventory is beginning to increase gradually in some parts of the country and homebuyers might be biding their time to enter the market given the prospect of lower rates,” added Kan.

Mortgage rates fell further to start this week, following a stock market rout Monday. They rose sharply again, however, on Tuesday following some more positive economic data.

“This is how things often play out when the bond market forces a quick move to extreme rate levels. For example, several of the biggest drops in daily mortgage rates have followed quick moves to long-term highs,” wrote Matthew Graham, chief operating officer at Mortgage News Daily.

Source link

Business

Further rate cuts could fuel house price rises, says Halifax

Published

1 week ago

August 7, 2024

worlddailyinfo

Lower mortgage rates and more interest rate cuts could fuel a “modest” rise in house prices for the rest of this year, Halifax has said.

The mortgage lender’s prediction came after property prices increased marginally in July following a flat few months.

Halifax said recent mortgage rate drops were “encouraging” for first-time buyers, those moving along the housing ladder or those refinancing.

But it warned affordability challenges and lack of available properties still posed problems for buyers.

“Against the backdrop of lower mortgage rates and potential further [Bank of England] base rate reductions, we anticipate house prices to continue a modest upward trend throughout the remainder of this year,” Amanda Bryden, head of mortgages at Halifax said.

Last week the Bank of England lowered interest rates to 5% – the first cut since the start of the pandemic in March 2020.

The Bank’s rate dictates the cost of borrowing set by High Street banks and money lenders for the likes of mortgages and credit cards.

The UK’s largest lender said a typical property cost £291,268 in July, up more than £2,200 compared to the previous month.

Source link